Xenon Pharmaceuticals Investor Presentation — December 2021

Document content

www.xenon -pharma.com NASDAQ: XENE

Summary of Results from the “X -TOLE” Study

FRIDAY, DECEMBER 3, 2021AES 2021 SymposiumXEN1101 Next -Gen KV7 Channel Opener

▪Only -in-class KV7 potassium channel modulator to

treat adult focal seizures

▪Novel MOA for rational polypharmacy

▪Designed to address limitations of first -gen KV7

modulator, ezogabine

•Higher in vitro and in vivo potency

•Lacks the chemical properties that could form

▪Improved seizure reduction

▪Potential to treat common comorbidities, such as

Addressing previous limitations, enhancing the KV7 opportunity

AES 2021 SYMPOSIUM | DECEMBER 3, 2021X-TOLE Study Schema

3 AES 2021 SYMPOSIUM | DECEMBER 3, 2021Primary / Secondary Objectives of X -TOLE Study

4OBJECTIVES ENDPOINTSPrimary ObjectivesTo assess the efficacy of XEN1101 compared

to placebo on focal seizure frequency in

adults with focal epilepsy taking 1 to 3 ASMs

in the double -blind period (DBP)•Median percent change (MPC) in monthly (28 days) focal seizure frequency from baseline to DBP for

XEN1101 versus placebo

To assess the safety and tolerability of

XEN1101 in adults with focal epilepsy taking

1 to 3 ASMs in the DBPIn the DBP:

•Severity and frequency of associated adverse events (AEs)/serious adverse events (SAEs)

•Clinically significant changes in clinical laboratory findings

•Clinically significant changes in 12 -lead ECG

•Change in suicidality risk as assessed by the C -SSRS including increase in suicidal thoughts or an

•Clinically significant changes in vital signs including blood pressure, pulse, or weight

•Clinically significant changes in urological symptoms including retention as measured by the American

Urological Association (AUA) Symptom IndexSecondary

Preview truncated — download the full document for the complete content.